This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can Surgery Partners (SGRY) Climb 40% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.5% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Save Your Portfolio by Getting Rid of These 4 Toxic Stocks
by Rimmi Singhi
Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.
Surgery Partners (SGRY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -25.00% and 0.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
by Zacks Equity Research
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
5 Medical Services Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.
Down 26.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Surgery Partners (SGRY)
by Zacks Equity Research
Surgery Partners (SGRY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Surgery Partners (SGRY) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 100.00% and -0.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -20.00% and 1.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
by Zacks Equity Research
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
Bear of the Day: Surgery Partners (SGRY)
by David Bartosiak
Somebody needs to come in and give earnings a boost, stat!
Are Options Traders Betting on a Big Move in Surgery Partners (SGRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Surgery Partners (SGRY) stock based on the movements in the options market lately.
Surgery Partners (SGRY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -76.67% and 10.57%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Surgery Partners (SGRY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
by Zacks Equity Research
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
Near-Term Outlook Tepid for Medical Services Industry
by Urmimala Biswas
This sector witnesses growing demand for telemedicine-focused online medical services amid the pandemic.
Surgery Partners (SGRY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 5.88% and 1.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Surgery Partners (SGRY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 41.38% and 16.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Q4 Earnings Lag Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -16.67% and 2.60%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You Looking for a Top Momentum Pick? Why Surgery Partners (SGRY) is a Great Choice
by Zacks Equity Research
Does Surgery Partners (SGRY) have what it takes to be a top stock pick for momentum investors? Let's find out.